[5-methyl-2-(triazol-2-yl)phenyl]-[(2S)-2-(5-phenylpyrazolidin-3-yl)pyrrolidin-1-yl]methanone
C23H26N6O — CID 134611818
Data last refreshed: (MolForge compound catalog, from PubChem)
About [5-methyl-2-(triazol-2-yl)phenyl]-[(2S)-2-(5-phenylpyrazolidin-3-yl)pyrrolidin-1-yl]methanone
[5-methyl-2-(triazol-2-yl)phenyl]-[(2S)-2-(5-phenylpyrazolidin-3-yl)pyrrolidin-1-yl]methanone (PubChem CID 134611818) has the molecular formula C23H26N6O and a molecular weight of 402.50 g/mol. Its IUPAC name is [5-methyl-2-(triazol-2-yl)phenyl]-[(2S)-2-(5-phenylpyrazolidin-3-yl)pyrrolidin-1-yl]methanone.
Molecular Properties
| Compound Name | [5-methyl-2-(triazol-2-yl)phenyl]-[(2S)-2-(5-phenylpyrazolidin-3-yl)pyrrolidin-1-yl]methanone |
|---|---|
| PubChem CID | 134611818 |
| Molecular Formula | C23H26N6O |
| Molecular Weight | 402.50 g/mol |
| Exact Mass | 402.22 |
| IUPAC Name | [5-methyl-2-(triazol-2-yl)phenyl]-[(2S)-2-(5-phenylpyrazolidin-3-yl)pyrrolidin-1-yl]methanone |
| SMILES | Cc1ccc(-n2nccn2)c(C(=O)N2CCC[C@H]2C2CC(c3ccccc3)NN2)c1 |
| InChI | InChI=1S/C23H26N6O/c1-16-9-10-21(29-24-11-12-25-29)18(14-16)23(30)28-13-5-8-22(28)20-15-19(26-27-20)17-6-3-2-4-7-17/h2-4,6-7,9-12,14,19-20,22,26-27H,5,8,13,15H2,1H3/t19?,20?,22-/m0/s1 |
| InChIKey | BZVOCJOBXWBVGN-AOMIVXANSA-N |
| XLogP | 2.79 |
| TPSA | 75.08 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 30 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 402.50 |
| LogP ≤ 5 | 2.79 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 134611818 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.